Dalbavancin: a novel lipoglycopeptide antibacterial

Area of Science:

• Pharmacology
• Infectious Diseases

Background:

• Dalbavancin is a novel lipoglycopeptide antibacterial agent.
• It exhibits in vitro activity against Gram-positive pathogens, including methicillin-susceptible and resistant Staphylococcus aureus.

Purpose of the Study:

• To review the in vitro and in vivo activity, pharmacokinetics, and clinical efficacy and safety of dalbavancin.
• To discuss the potential clinical role of dalbavancin based on current trial data.

Main Methods:

• In vitro susceptibility testing against Gram-positive pathogens.
• Evaluation in animal infection models.
• Review of Phase II and III clinical trial data for skin and soft-tissue infections and catheter-related bloodstream infections.

Main Results:

• Dalbavancin demonstrated favorable minimum inhibitory concentration ranges against Staphylococcus aureus compared to existing agents.
• High protein binding (>90%) contributes to a prolonged half-life (149-300 hours), enabling once-weekly dosing.
• Clinical trials showed efficacy and tolerability comparable to vancomycin, linezolid, and beta-lactams for specific infections.

Conclusions:

• Dalbavancin is a promising novel antibacterial agent with a favorable pharmacokinetic profile.
• Its efficacy and safety in treating Gram-positive infections, particularly those caused by Staphylococcus aureus, have been demonstrated in clinical trials.
• Further Phase III trials are anticipated to fully establish its clinical utility.